Form 4: Opus Genetics President Acquires 10,000 Shares in Open Market Transaction

Opus Genetics President, Benjamin R. Yerxa, purchased 10,000 shares of common stock at $0.9834 per share on November 21, 2024.

Summary

• Benjamin R. Yerxa, President of Opus Genetics, Inc., acquired 10,000 shares of the company's common stock.
• The transaction occurred on November 21, 2024.
• The purchase price was $0.9834 per share.
• Following the transaction, Mr. Yerxa directly owns 342,800 shares of Opus Genetics common stock.

Sentiment

Score: 6

Explanation: The document is a routine filing related to an insider stock purchase. It is neither overwhelmingly positive nor negative, but the purchase by an executive is generally viewed as a positive sign.

Positives

• The purchase of shares by a company executive can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who trade their company's stock. It provides transparency into the transactions of company executives.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the United States.
• The transaction is typical for executives who are acquiring or disposing of company stock.
• The filing is consistent with SEC regulations regarding insider trading.

Stakeholder Impact

• The purchase of shares by a company executive may increase investor confidence.

Key Dates

Keywords

Opus Genetics, insider trading, stock purchase, Benjamin R. Yerxa, common stock, Form 4